Oncotelic says safety panel clears Sapu003 Phase 1b trial to escalate dose

ONCOTELIC THERAPEUTICS INC

ONCOTELIC THERAPEUTICS INC

OTLC

0.00
  • Oncotelic cleared the initial safety cohort in its Phase 1b SP-03-B101 trial of Sapu003, an intravenous everolimus formulation.
  • An independent Safety Review Committee reported no dose-limiting toxicities in the first three patients during the 28-day evaluation window.
  • The committee recommended escalation to the next planned dose level under the protocol’s BOIN dose-escalation design.
  • The company started expanding the SP-03-B101 program into Europe to add sites and speed enrollment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncotelic Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607070930PRIMZONEFULLFEED9758059) on July 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.